Eravacycline - Tetraphase Pharmaceuticals

Drug Profile

Eravacycline - Tetraphase Pharmaceuticals

Alternative Names: TP-434

Latest Information Update: 15 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tetraphase Pharmaceuticals
  • Class Acetamides; Antibacterials; Pyrrolidines; Small molecules; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Intra-abdominal infections
  • No development reported Respiratory tract infections
  • Discontinued Urinary tract infections

Most Recent Events

  • 11 Jun 2018 Pooled efficacy data from IGNITE-1 and IGNITE-4 in Intra-abdominal infections released by Tetraphase Pharmaceuticals
  • 05 Jun 2018 Everest Medicines files an IND application with the China's Food and Drug Administration (CFDA) in China for a phase III trial in Intra-abdominal infections
  • 03 May 2018 Tetraphase Pharmaceuticals anticipates approval of eravacycline for complicated intra-abdominal infections in USA and Europe in Q3 2018 and 2H 2018, respectively
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top